<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04182620</url>
  </required_header>
  <id_info>
    <org_study_id>GCO 40-5118</org_study_id>
    <secondary_id>IRB 19-02659</secondary_id>
    <nct_id>NCT04182620</nct_id>
  </id_info>
  <brief_title>Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation</brief_title>
  <acronym>ULTRA-HFIB</acronym>
  <official_title>Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vivek Reddy</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Icahn School of Medicine at Mount Sinai</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the ULTRA-HFIB Pilot is to determine the role of adjunctive renal denervation
      (RDN) in the prevention of Atrial Fibrillation (AF) recurrence in patients scheduled for an
      AF ablation procedure. Patients will be randomized to either i) AF ablation (Control) or ii)
      AF ablation + renal sympathetic denervation (Intervention).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the ULTRA-HFIB Pilot is to determine the role of adjunctive renal denervation
      (RDN) in the prevention of AF recurrence in patients scheduled for an AF ablation procedure.
      Patients will be randomized to either i) AF ablation (Control) or ii) AF ablation + renal
      sympathetic denervation (Intervention). This is a prospective, controlled, single-blind,
      randomized trial. The pilot study will be conducted in up to 11 clinical sites in the United
      States and Europe.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 8, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Patients will be blinded until the 6 month visit, at which time they will be un-blinded prior to the follow up CT/MRI. The Clinical Events Committee and Echo Core Lab will remain blinded throughout the trial. In general, the CEC will be blinded to the treatment arms. However, once the nature of the event has been adjudicated, the blind will be broken for that individual patient as necessary to enable the CEC to determine relatedness to the study device.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Single-procedure freedom from AT/AF/AFL recurrence ≥ 30 seconds</measure>
    <time_frame>12 months</time_frame>
    <description>Single-procedure freedom from AT/AF/AFL recurrence ≥ 30 seconds off Class I and III AADs (after the 90-day blanking period), defined by absence of any electrocardiographically documented AT/AF.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Freedom from AT/AF/AFL recurrence</measure>
    <time_frame>12 months</time_frame>
    <description>Freedom from AT/AF/AFL recurrence through 12 months (excluding a 90-day blanking period from the initial ablation procedure) irrespective of AADs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of procedural adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of procedural adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Atrial Fibrillation Effect on QualiTy-of-Life (AFEQT) questionnaire</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life instrument (AFEQT) is a 20-item disease-specific scale developed to capture subjective ratings of AF disease and treatment burden. Full range score from 0-100, with higher score indicating higher level of quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in office systolic blood pressure change from baseline to 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>Change in office systolic blood pressure change from baseline to 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF burden at 6 months</measure>
    <time_frame>6 months</time_frame>
    <description>AF burden at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AF burden at 12 months</measure>
    <time_frame>12 months</time_frame>
    <description>AF burden at 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Catheter ablation + renal denervation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Catheter ablation + renal denervation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Catheter ablation only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Catheter ablation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>renal denervation</intervention_name>
    <description>Renal denervation using the Paradise renal denervation system - a dedicated RDN catheter that delivers a circumferential ring of ablative ultrasound energy</description>
    <arm_group_label>Catheter ablation + renal denervation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Catheter ablation</intervention_name>
    <description>Catheter ablation - one of the most common procedures performed by Cardiac Electrophysiologists for atrial fibrillation</description>
    <arm_group_label>Catheter ablation + renal denervation</arm_group_label>
    <arm_group_label>Catheter ablation only</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age ≥ 18 years of age;

          -  Planned for first-ever AF ablation procedure (paroxysmal or persistent); prior to
             randomization, a technically successful AF ablation procedure (defined as involving
             pulmonary vein isolation, as well as bidirectional block of any attempted anatomic
             lesion sets such as cavotricuspid isthmus line, roofline, mitral line and superior
             vena cava isolation) must have been completed

          -  History of hypertension and either:

               -  Documented history of SBP≥160 or DBP≥100 or;

               -  Receiving ≥1 antihypertensive medication;

          -  Willingness to adhere to study restrictions and comply with all post-procedural
             follow-up requirements

        Exclusion Criteria:

          -  Long-standing persistent AF (&gt;12 months);

          -  Individual with valvular AF or AF due to a reversible cause;

          -  Prior left atrial catheter or surgical ablation for an atrial arrhythmia (before this
             index procedure);

          -  Prior left atrial surgery (such as mitral valve surgery or surgical ASD repair).

          -  Prior treatment with other devices for hypertension including but not limited to ROX
             Coupler, Mobius stent, and/or the CVRx barostimulator device.

          -  NYHA class IV congestive heart failure;

          -  Individual has renal artery anatomy that is ineligible for treatment (as determined by
             pre-procedural CT/MRI);

               -  Main renal artery diameter &lt; 3.5 mm or &gt; 8.0 mm

               -  Main renal treatable artery length &lt; 20 mm (length may include proximal branches)

               -  Presence of renal artery stenosis of any origin ≥ 30%

               -  Accessory arteries with diameter ≥ 2 mm &lt; 3.5 mm

               -  Calcification in renal arteries

               -  Prior renal denervation procedure

               -  Presence of abnormal kidney tumors

               -  Renal artery aneurysm

               -  Pre-existing renal stent or history of renal artery angioplasty

               -  Pre-existing aortic stent or history of aortic aneurysm

               -  Fibromuscular disease of the renal arteries

               -  Iliac/femoral artery stenosis precluding insertion of the Paradise Catheter

          -  Individual has an estimated glomerular filtration rate (eGFR) of less than
             40mL/min/1.73m2, using the MDRD calculation;

          -  Inability to undergo AF catheter ablation (e.g., presence of a left atrial thrombus,
             contraindication to all anticoagulation)

          -  Individual with known allergy to contrast medium not amendable to treatment.

          -  Life expectancy &lt; 1 year for any medical condition.

          -  Individual has experienced a myocardial infarction, unstable angina, cerebrovascular
             accident, or heart failure admission within 3 months of the baseline visit.

          -  Documented history of chronic active inflammatory bowel disorders such as Crohn's
             disease or ulcerative colitis.

          -  Female participants who are pregnant or nursing.

          -  Individual has known secondary hypertension.

          -  Individual has a single functioning kidney (either congenitally or iatrogenically)

          -  Individual has a known, unresolved history of drug use or alcohol dependency, lacks
             the ability to comprehend or follow instructions, or would be unlikely or unable to
             comply with study follow-up requirements.

          -  Patients concurrently enrolled in any other investigational drug or device trial that
             would interfere with the conduction of this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vivek Reddy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Icahn School of Medicine at Mount Sinai</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sam Cammack, MA, MPH</last_name>
    <phone>212-824-8931</phone>
    <email>sam.cammack@mountsinai.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Betsy Ellsworth, MSN, ANP</last_name>
    <phone>212-824-8902</phone>
    <email>betsy.ellsworth@mountsinai.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Arizona Heart Institute</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie Raymond</last_name>
      <phone>602-842-7352</phone>
      <email>sraymond@azheartrhythm.com</email>
    </contact>
    <investigator>
      <last_name>Vijendra Swarup, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Scripps Clinic</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Douglas Gibson, MD</last_name>
    </contact>
    <investigator>
      <last_name>Douglas Gibson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tiffany Hart</last_name>
      <phone>773-702-0535</phone>
      <email>thart@medicine.bsd.uchicago.edu</email>
    </contact>
    <investigator>
      <last_name>Roderick Tung, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kevin Marzotto</last_name>
      <phone>617-726-0280</phone>
      <email>kmarzotto@mgh.harvard.edu</email>
    </contact>
    <contact_backup>
      <last_name>Grace Ha</last_name>
      <phone>617-726-0280</phone>
      <email>gha2@mgh.harvard.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Moussa Mansour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Briita Wanhala</last_name>
      <phone>313-916-9575</phone>
      <email>bwanhal1@hfhs.org</email>
    </contact>
    <investigator>
      <last_name>Marc Lahiri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mount Sinai Hospital</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>William Whang, MD</last_name>
      <phone>212-241-7114</phone>
      <email>william.whang@mountsinai.org</email>
    </contact>
    <contact_backup>
      <last_name>Jonas Leavitt, BS</last_name>
      <phone>212-824-8930</phone>
      <email>jonas.leavitt@mountsinai.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Susan Hejl</last_name>
      <phone>216-445-6817</phone>
      <email>hejls@ccf.org</email>
    </contact>
    <investigator>
      <last_name>Mohamed Kanj, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Cardiac Arrhythmia Research Foundation</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Deb Cardinal</last_name>
      <phone>512-431-4868</phone>
      <email>dscardinal@austinheartbeat.com</email>
    </contact>
    <investigator>
      <last_name>Andrea Natale, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Na Homolce Hospital</name>
      <address>
        <city>Prague</city>
        <zip>15030</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stepan Kralovec</last_name>
      <phone>00420 777671069</phone>
      <email>stepan.kralovec@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Petr Neuzil, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Herzzentrum Leipzig</name>
      <address>
        <city>Berlin</city>
        <state>Brandenburg</state>
        <zip>13347</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Kathrin Funkat</last_name>
      <email>anne-kathrin.funkat@leipzig-heart.de</email>
    </contact>
    <investigator>
      <last_name>Bettina Pfannmüller, PD Dr. med.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universität des Saarlandes</name>
      <address>
        <city>Homburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christina Koch</last_name>
      <phone>+49 6841 161 5854</phone>
      <email>Christina.koch@uks.edu</email>
    </contact>
    <investigator>
      <last_name>Christian Ukena, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Germany</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>November 27, 2019</study_first_submitted>
  <study_first_submitted_qc>November 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 2, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Icahn School of Medicine at Mount Sinai</investigator_affiliation>
    <investigator_full_name>Vivek Reddy</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>renal denervation</keyword>
  <keyword>atrial fibrillation</keyword>
  <keyword>cardiology</keyword>
  <keyword>electrophysiology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

